RU2209064C2 - Новое применение в медицинских целях - Google Patents

Новое применение в медицинских целях Download PDF

Info

Publication number
RU2209064C2
RU2209064C2 RU98101105/14A RU98101105A RU2209064C2 RU 2209064 C2 RU2209064 C2 RU 2209064C2 RU 98101105/14 A RU98101105/14 A RU 98101105/14A RU 98101105 A RU98101105 A RU 98101105A RU 2209064 C2 RU2209064 C2 RU 2209064C2
Authority
RU
Russia
Prior art keywords
compound
formula
active ingredient
pharmaceutical preparation
symptoms
Prior art date
Application number
RU98101105/14A
Other languages
English (en)
Other versions
RU98101105A (ru
Inventor
Ларс ФЕНДРИКС (SE)
Ларс Фендрикс
Андерс ПЕТТЕРСОН (SE)
Андерс Петтерсон
Original Assignee
Фармакор Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармакор Аб filed Critical Фармакор Аб
Publication of RU98101105A publication Critical patent/RU98101105A/ru
Application granted granted Critical
Publication of RU2209064C2 publication Critical patent/RU2209064C2/ru

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Изобретение относится к медицине, а именно к гастроэнтерологии, и касается лечения симптомов функциональной диспепсии, связанных с нарушением способности гастродуоденальной слизистой нейтрализовать кислоту. Для этого используют производные бифенилтетразола общей формулы I, являющиеся антагонистами рецепторов ангиотензина II 1-го типа. Изобретение позволяет уменьшить симптомы функциональной диспепсии путем воздействия на ренин-ангиотензиновую систему. 3 с. и 7 з.п.ф-лы, 1 табл.

Description

Текст описания в факсимильном виде (см. графическую часть). Т3

Claims (10)

1. Применение соединения общей формулы I
Figure 00000001

в которой А представляет собой
Figure 00000002

Figure 00000003

Figure 00000004

Figure 00000005

Figure 00000006

Figure 00000007

Figure 00000008

Figure 00000009

Figure 00000010

Figure 00000011

Figure 00000012

Figure 00000013

Figure 00000014

или его физиологически приемлемой соли и/или стереохимического изомера в качестве активного ингредиента для производства медикамента, уменьшающего симптомы функциональной диспепсии, связанные с нарушением способности гастродуоденальной слизистой нейтрализовать кислоту.
2. Применение по п. 1 соединения формулы I, в которой А представляет собой I:1.
3. Применение по п. 1 соединения формулы I, в которой А представляет собой I:5.
4. Фармацевтический препарат для применения при профилактике и/или лечении симптомов функциональной диспепсии, связанных с нарушением способности гастродуоденальной слизистой нейтрализовать кислоту, в котором активным ингредиентом является соединение по п.1.
5. Фармацевтический препарат по п.4 в форме стандартной дозы.
6. Фармацевтический препарат по пп.4 и 5, содержащий активный ингредиент в сочетании с фармацевтически приемлемым носителем.
7. Фармацевтический препарат по пп.4-6, содержащий в качестве активного ингредиента соединение формулы I, в которой А представляет собой I:1.
8. Фармацевтический препарат по пп.4-6, содержащий в качестве активного ингредиента соединение формулы I, в которой А представляет собой I:5.
9. Способ профилактики и лечения симптомов функциональной диспепсии, связанных с нарушением способности гастродуоденальной слизистой нейтрализовать кислоту, у млекопитающих, включая человека, при котором эффективным количеством соединения по п.1 воздействуют на хозяина, нуждающегося в такой профилактике и лечении.
10. Способ по п.9, отличающийся тем, что воздействуют соединением формулы I, в которой А представляет собой I:1 или I:5.
RU98101105/14A 1995-06-19 1996-06-10 Новое применение в медицинских целях RU2209064C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9502219.0 1995-06-19
SE9502219A SE9502219D0 (sv) 1995-06-19 1995-06-19 Novel medical use

Publications (2)

Publication Number Publication Date
RU98101105A RU98101105A (ru) 1999-12-10
RU2209064C2 true RU2209064C2 (ru) 2003-07-27

Family

ID=20398663

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98101105/14A RU2209064C2 (ru) 1995-06-19 1996-06-10 Новое применение в медицинских целях

Country Status (28)

Country Link
US (1) US6096772A (ru)
EP (1) EP0840607B1 (ru)
JP (1) JPH11507921A (ru)
KR (1) KR19990023021A (ru)
CN (1) CN1091595C (ru)
AT (1) ATE214925T1 (ru)
AU (1) AU706660B2 (ru)
BR (1) BR9608472A (ru)
CA (1) CA2225175A1 (ru)
CZ (1) CZ289400B6 (ru)
DE (1) DE69620186T2 (ru)
DK (1) DK0840607T3 (ru)
EE (1) EE03385B1 (ru)
ES (1) ES2173294T3 (ru)
HK (1) HK1010152A1 (ru)
HU (1) HUP9901448A3 (ru)
IL (1) IL122659A (ru)
IS (1) IS4619A (ru)
MY (1) MY114716A (ru)
NO (1) NO975922L (ru)
NZ (1) NZ310606A (ru)
PT (1) PT840607E (ru)
RU (1) RU2209064C2 (ru)
SE (1) SE9502219D0 (ru)
SK (1) SK172197A3 (ru)
UA (1) UA55387C2 (ru)
WO (1) WO1997000070A1 (ru)
ZA (1) ZA964690B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
SE9800550D0 (sv) * 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
EP1438027A1 (en) * 2001-10-25 2004-07-21 DepoMed, Inc. Methods of treatment using a gastric retained losartan dosage
ATE487478T1 (de) * 2003-01-30 2010-11-15 Lek Pharmaceuticals Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US8979838B2 (en) 2010-05-24 2015-03-17 Arthrocare Corporation Symmetric switching electrode method and related system
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
GB2263635A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substitiuted triazoles as neurotensin antagonists
US5250558A (en) * 1992-01-28 1993-10-05 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis
GB2263638A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrazoles, isoxazoles and isothiazoles as neurotensin antagonists
GB2263639A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
GB2263637A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted imidazo-fused 6-membered carbocycle or heterocycle as neurotensin antagonists
DE4203872A1 (de) * 1992-02-11 1993-08-12 Thomae Gmbh Dr K Imidazo(1,2-a)pyridine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5212195A (en) * 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ЕР 0253310 А2 (DU PONT), 20.01.1998. ЕР 04591036 A1 (TAKEDA CHEMICAL INDUSTRIES LTD), 04.12.1991. ГЕЛЛЕР Л.И. и др. Синдром неязвенной диспепсии, Клиническая медицина, 1993, т.71, №1, с.22-25. КОРЖАК О.Л. и др. Фармакологический анализ эффекта ангиотензина на стимуляцию желудочной секреции, Физиологический журнал Украины, 1994, т.40, №5-6, реферат. *

Also Published As

Publication number Publication date
AU1184097A (en) 1997-01-15
ZA964690B (en) 1996-12-19
EP0840607B1 (en) 2002-03-27
ATE214925T1 (de) 2002-04-15
CN1192681A (zh) 1998-09-09
HUP9901448A3 (en) 2002-03-28
NO975922D0 (no) 1997-12-16
US6096772A (en) 2000-08-01
CZ373097A3 (cs) 1998-05-13
IL122659A0 (en) 1998-08-16
CN1091595C (zh) 2002-10-02
HK1010152A1 (en) 1999-06-17
EE03385B1 (et) 2001-04-16
DK0840607T3 (da) 2002-05-06
UA55387C2 (ru) 2003-04-15
CA2225175A1 (en) 1997-01-03
NO975922L (no) 1997-12-16
DE69620186T2 (de) 2002-10-31
ES2173294T3 (es) 2002-10-16
BR9608472A (pt) 1998-12-29
HUP9901448A2 (hu) 2000-04-28
WO1997000070A1 (en) 1997-01-03
SE9502219D0 (sv) 1995-06-19
PT840607E (pt) 2002-09-30
CZ289400B6 (cs) 2002-01-16
AU706660B2 (en) 1999-06-17
NZ310606A (en) 2001-03-30
MX9710002A (es) 1998-07-31
DE69620186D1 (de) 2002-05-02
EE9700366A (et) 1998-06-15
EP0840607A1 (en) 1998-05-13
MY114716A (en) 2002-12-31
KR19990023021A (ko) 1999-03-25
SK172197A3 (en) 1998-07-08
IS4619A (is) 1997-11-25
JPH11507921A (ja) 1999-07-13
IL122659A (en) 2003-01-12

Similar Documents

Publication Publication Date Title
ATE260646T1 (de) Schnell zerfallende orale dosierungsform
RU2220723C2 (ru) Средство и способ лечения или профилактики артериосклероза
EE04800B1 (et) Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks
EA200500088A1 (ru) Трициклические модуляторы ядерного рецептора стероидного гормона
RU95102778A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен
RU99119084A (ru) Фармацевтические композиции для контролируемого высвобождения активных веществ
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
RU2001111880A (ru) Композиции для перорального введения, содержащие луфенурон и нитенпирам, для борьбы с блохами
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
RU2209064C2 (ru) Новое применение в медицинских целях
RU2002117649A (ru) Фармацевтические композиции, содержащие золмитриптан
RU2000116547A (ru) Применение замещенных аминометил-хроманов для предотвращения дегенерации и для ускорения регенерации нервных клеток
KR930003915A (ko) 장기 이식에 있어서의 거부 반응 치료 약제
KR20040000446A (ko) 중간 용량의 lhrh 길항제를 사용한 치매 및 퇴행성신경질환의 치료
KR970061249A (ko) 골다공증을 치료 또는 방지하기 위한 조성물
RU94045866A (ru) Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, способ лечения
RU97120700A (ru) Новое фармакологическое применение антагонистов a-ii рецептора
ZA922910B (en) Heterocylic pharmaceutical compounds preparation and use
RU98101105A (ru) Новое применение в медицинских целях
RU2011131532A (ru) Способ лечения бессонницы
RU2004131214A (ru) Способы лечения когнитивных расстройств
RU2005105302A (ru) Композиция бицифадина
RU98103388A (ru) (r)-5-бром-n-(1-этил-4-метилгексагидро-1н-1,4-диазепин-6-ил)-2-метокси-6-м етиламино-3-пиридинкарбоксамид, способ его получения и фармацевтическая композиция, содержащая указанное соединение
KR900701278A (ko) 바이러스 감염 치료용 담즙산
RU94032792A (ru) Применение 5нтiа - антагонистов для прекращения использования табака

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20030611